search
Back to results

Heat Therapy in Patients With Type 2 Diabetes Mellitus (HEATED)

Primary Purpose

Diabetes Mellitus, Type 2, Insulin Resistance

Status
Withdrawn
Phase
Not Applicable
Locations
Hungary
Study Type
Interventional
Intervention
Passive heating
Thermoneutral
Sponsored by
University of Pecs
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring insulin resistance, balneotherapy, additional therapy, alternative therapy, heat shock proteins

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patient with type 2 diabetes diagnosed according to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) guidelines
  • serum glycated hemoglobin (HbA1c) level between 7 and 10% (53-86 mmol/mol)
  • signed written informed consent form

Exclusion Criteria:

  • other types of diabetes mellitus
  • patients with poor glycaemic control or unstable diabetes
  • patients with known serious comorbidity and/ or with advanced macrovascular complications
  • active bacterial infection or treatment with antibiotics within 3 weeks
  • open wounds or skin lesions
  • history of skin-related conditions or sensitivity to prolonged water immersion or exposure to pool chemicals
  • severe psychiatric pathology or psychosis
  • pregnancy or breastfeeding
  • judgment by medical provider that heat therapy/ hydrotherapy poses an undue burden or risk
  • participating in other ongoing clinical trials
  • heat or balneotherapy in the past 3 months
  • morbid obesity (body mass index > 40 kg/m2)
  • steroid treatment
  • active autoimmune diseases
  • coronavirus disease 2019 (COVID-19) in the past 3 months

Sites / Locations

  • Institute for Translational Medicine, University of Pécs

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Passive heating

Thermoneutral

Arm Description

Patients will be randomized to receive whole-body passive heating via 38°C natural thermal mineral water baths.

Patients randomized to the comparator group will dip in thermoneutral natural thermal mineral water (30-32°C).

Outcomes

Primary Outcome Measures

Change in hemoglobin A1c level
The absolut changes in the hemoglobin A1c from baseline to 12-weeks between the two groups will be compared.

Secondary Outcome Measures

Change in hemoglobin A1c level
Absolute change from baseline to follow-up in hemoglobin A1c level.
Change in fasting plasma glucose
Absolute change from baseline to follow-up in fasting plasma glucose.
Change in fasting insulin
Absolute change from baseline to follow-up in fasting insulin.
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Absolute change from baseline to follow-up in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).
Decrease of daily insulin dose
Absolute change from baseline to follow-up of the daily insulin dose.
Change in body mass index
Absolute change from baseline to follow-up in body mass index. Weight and height will be combined to report BMI in kg/m^2.
Change in mean blood pressure
Absolute change from baseline to follow-up in mean blood pressure.
Change in heart output
Absolute change from baseline to follow-up in heart output.
Change in the prevalence of electrocardiogram events
Change in the prevalence of electrocardiogram events from baseline to follow-up. Electrocardiogram events represent a composite endpoint of any new events detected using a 12 lead electrocardiogram (e.g., myocardial infarction, atrial fibrillation, atrioventricular block, etc.).
Change in the proportion of hypertension
Absolute change from baseline to follow-up in the proportion of hypertension
Change in the proportion of retinopathy
Absolute change from baseline to follow-up in the proportion of retinopathy
Change in the proportion of nephropathy
Absolute change from baseline to follow-up in the proportion of nephropathy
Change in the proportion of neuropathy
Absolute change from baseline to follow-up in the proportion of neuropathy
Change in total cholesterol level
Absolute change from baseline to follow-up in total cholesterol level.
Change in low-density lipoprotein cholesterol level
Absolute change from baseline to follow-up in low-density lipoprotein cholesterol level.
Change in high-density lipoprotein cholesterol level
Absolute change from baseline to follow-up in high-density lipoprotein cholesterol level.
Change in triglyceride level
Absolute change from baseline to follow-up in triglyceride level.
Change in alkaline phosphatase (ALP)
Absolute change from baseline to follow-up in alkaline phosphatase (ALP).
Change in alanine transaminase (ALT)
Absolute change from baseline to follow-up in alanine transaminase (ALT).
Change in aspartate transaminase (AST)
Absolute change from baseline to follow-up in aspartate transaminase (AST).
Change in gamma-glutamyl transferase (GGT).
Absolute change from baseline to follow-up in gamma-glutamyl transferase (GGT).
Change in glomerular filtration rate
Absolute change from baseline to follow-up in glomerular filtration rate.
Change in creatinine level
Absolute change from baseline to follow-up in creatinine.
Change in thrombocyte aggregation
Absolute change from baseline to follow-up in thrombocyte aggregation.
Heat Shock Protein expression
Difference between the two groups in the level of protein expression using flow cytometry.
Insulin signaling in polymorphonuclear cells
Difference between the two groups in the level of protein expression using flow cytometry.
Lipidom of polymorphonuclear cells
High sensitivity shotgun mass spectrometry will be used to characterize the lipidome of plasma, and polymorphonuclear blood cells.
Lipidom of plasma cells
High sensitivity shotgun mass spectrometry will be used to characterize the lipidome of plasma, and polymorphonuclear blood cells.
Change in obstructive sleep apnea proportion
Change in the proportion of obstructive sleep apnea from baseline to follow-up
Change in the proportion of abnormal overnight pulse oximetry
Absolute change from baseline to follow-up in the proportion of abnormal overnight pulse oximetry.
Change in 24-hour blood pressure
Absolute change from baseline to follow-up in 24-hour blood pressure

Full Information

First Posted
January 5, 2022
Last Updated
April 18, 2023
Sponsor
University of Pecs
search

1. Study Identification

Unique Protocol Identification Number
NCT05237219
Brief Title
Heat Therapy in Patients With Type 2 Diabetes Mellitus
Acronym
HEATED
Official Title
The Effect of HEAT Therapy on patiEnts With Type 2 Diabetes Mellitus (HEATED): Protocol of a Randomized, Two-arm Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Withdrawn
Why Stopped
The human resources required to start enrollment were not available anymore.
Study Start Date
May 1, 2022 (Anticipated)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
June 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pecs

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Type 2 diabetes mellitus (T2DM) is a significant burden worldwide. In addition to lifestyle intervention, heat therapy has been shown to be effective in improving glycemic control. To date, there are no randomized, controlled trials investigating the efficacy of heat therapy in T2DM. Our aim is to investigate whether heat therapy with natural mineral water can improve blood glucose status in T2DM patients. The HEATED study is a two-arm, randomized, controlled study. Patients with T2DM were randomly assigned to Group A (bath in 38 ° C natural thermal mineral water) or Group B (bath in thermoneutral water - 30-32 ° C). Both groups participate in up to five interventions per week, representing 50 to 60 heat therapies over the 12-week study. Each intervention lasts 30 minutes, preceded by a medical examination.
Detailed Description
Type 2 diabetes mellitus (T2DM) is a significant burden worldwide. In addition to lifestyle intervention, heat therapy has been shown to be effective in improving glycemic control. To date, there are no randomized, controlled trials investigating the efficacy of heat therapy in T2DM. The study aims to investigate whether heat therapy with natural mineral water can improve blood glucose status in T2DM patients. The HEATED study is a two-arm, randomized, controlled study. Patients with T2DM will be randomly assigned to Group A (bath in 38 ° C natural thermal mineral water) or Group B (bath in thermoneutral water - 30-32 ° C). Both groups will participate in up to five interventions per week, representing 50 to 60 heat therapies over the 12-week study. Each intervention will last 30 minutes, preceded by a medical examination. At baseline, patients' T2DM status will be recorded and possible micro- and macrovascular complications of T2DM are assessed by physical and laboratory tests. In addition, sensory and autonomic neuropathy will be assessed using Neurometer, Neuropad, and 128 Hz tuning fork tests. Quality of life will be assessed using the SF-36 questionnaire. In addition to baseline, patient data will be recorded at 4, 8, and 12 weeks. During routine blood collection, biobank storage will be performed via plus blood samples collection. The primary endpoint will be the change from baseline in glycated hemoglobin by week 12 in both groups. Based on a preliminary estimate of the number of items, 65 patients per group are planned to be included in the HEATED study. The results of the study described above may provide information on the utility of heat therapy in type 2 diabetics. Using the samples stored in the biobank, further analyzes will be performed at the end of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Insulin Resistance
Keywords
insulin resistance, balneotherapy, additional therapy, alternative therapy, heat shock proteins

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Passive heating
Arm Type
Experimental
Arm Description
Patients will be randomized to receive whole-body passive heating via 38°C natural thermal mineral water baths.
Arm Title
Thermoneutral
Arm Type
Active Comparator
Arm Description
Patients randomized to the comparator group will dip in thermoneutral natural thermal mineral water (30-32°C).
Intervention Type
Procedure
Intervention Name(s)
Passive heating
Intervention Description
Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
Intervention Type
Procedure
Intervention Name(s)
Thermoneutral
Intervention Description
Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
Primary Outcome Measure Information:
Title
Change in hemoglobin A1c level
Description
The absolut changes in the hemoglobin A1c from baseline to 12-weeks between the two groups will be compared.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in hemoglobin A1c level
Description
Absolute change from baseline to follow-up in hemoglobin A1c level.
Time Frame
4 and 8 weeks
Title
Change in fasting plasma glucose
Description
Absolute change from baseline to follow-up in fasting plasma glucose.
Time Frame
4,8, and 12-weeks
Title
Change in fasting insulin
Description
Absolute change from baseline to follow-up in fasting insulin.
Time Frame
4,8, and 12-weeks
Title
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Description
Absolute change from baseline to follow-up in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).
Time Frame
4,8, and 12-weeks
Title
Decrease of daily insulin dose
Description
Absolute change from baseline to follow-up of the daily insulin dose.
Time Frame
4,8, and 12-weeks
Title
Change in body mass index
Description
Absolute change from baseline to follow-up in body mass index. Weight and height will be combined to report BMI in kg/m^2.
Time Frame
4,8, and 12-weeks
Title
Change in mean blood pressure
Description
Absolute change from baseline to follow-up in mean blood pressure.
Time Frame
4,8, and 12-weeks
Title
Change in heart output
Description
Absolute change from baseline to follow-up in heart output.
Time Frame
4,8, and 12-weeks
Title
Change in the prevalence of electrocardiogram events
Description
Change in the prevalence of electrocardiogram events from baseline to follow-up. Electrocardiogram events represent a composite endpoint of any new events detected using a 12 lead electrocardiogram (e.g., myocardial infarction, atrial fibrillation, atrioventricular block, etc.).
Time Frame
4,8, and 12-weeks
Title
Change in the proportion of hypertension
Description
Absolute change from baseline to follow-up in the proportion of hypertension
Time Frame
4,8, and 12-weeks
Title
Change in the proportion of retinopathy
Description
Absolute change from baseline to follow-up in the proportion of retinopathy
Time Frame
4,8, and 12-weeks
Title
Change in the proportion of nephropathy
Description
Absolute change from baseline to follow-up in the proportion of nephropathy
Time Frame
4,8, and 12-weeks
Title
Change in the proportion of neuropathy
Description
Absolute change from baseline to follow-up in the proportion of neuropathy
Time Frame
4,8, and 12-weeks
Title
Change in total cholesterol level
Description
Absolute change from baseline to follow-up in total cholesterol level.
Time Frame
4,8, and 12-weeks
Title
Change in low-density lipoprotein cholesterol level
Description
Absolute change from baseline to follow-up in low-density lipoprotein cholesterol level.
Time Frame
4,8, and 12-weeks
Title
Change in high-density lipoprotein cholesterol level
Description
Absolute change from baseline to follow-up in high-density lipoprotein cholesterol level.
Time Frame
4,8, and 12-weeks
Title
Change in triglyceride level
Description
Absolute change from baseline to follow-up in triglyceride level.
Time Frame
4,8, and 12-weeks
Title
Change in alkaline phosphatase (ALP)
Description
Absolute change from baseline to follow-up in alkaline phosphatase (ALP).
Time Frame
4,8, and 12-weeks
Title
Change in alanine transaminase (ALT)
Description
Absolute change from baseline to follow-up in alanine transaminase (ALT).
Time Frame
4,8, and 12-weeks
Title
Change in aspartate transaminase (AST)
Description
Absolute change from baseline to follow-up in aspartate transaminase (AST).
Time Frame
4,8, and 12-weeks
Title
Change in gamma-glutamyl transferase (GGT).
Description
Absolute change from baseline to follow-up in gamma-glutamyl transferase (GGT).
Time Frame
4,8, and 12-weeks
Title
Change in glomerular filtration rate
Description
Absolute change from baseline to follow-up in glomerular filtration rate.
Time Frame
4,8, and 12-weeks
Title
Change in creatinine level
Description
Absolute change from baseline to follow-up in creatinine.
Time Frame
4,8, and 12-weeks
Title
Change in thrombocyte aggregation
Description
Absolute change from baseline to follow-up in thrombocyte aggregation.
Time Frame
4,8, and 12-weeks
Title
Heat Shock Protein expression
Description
Difference between the two groups in the level of protein expression using flow cytometry.
Time Frame
4,8, and 12-weeks
Title
Insulin signaling in polymorphonuclear cells
Description
Difference between the two groups in the level of protein expression using flow cytometry.
Time Frame
4,8, and 12-weeks
Title
Lipidom of polymorphonuclear cells
Description
High sensitivity shotgun mass spectrometry will be used to characterize the lipidome of plasma, and polymorphonuclear blood cells.
Time Frame
4,8, and 12-weeks
Title
Lipidom of plasma cells
Description
High sensitivity shotgun mass spectrometry will be used to characterize the lipidome of plasma, and polymorphonuclear blood cells.
Time Frame
4,8, and 12-weeks
Title
Change in obstructive sleep apnea proportion
Description
Change in the proportion of obstructive sleep apnea from baseline to follow-up
Time Frame
4,8, and 12-weeks
Title
Change in the proportion of abnormal overnight pulse oximetry
Description
Absolute change from baseline to follow-up in the proportion of abnormal overnight pulse oximetry.
Time Frame
4,8, and 12-weeks
Title
Change in 24-hour blood pressure
Description
Absolute change from baseline to follow-up in 24-hour blood pressure
Time Frame
4,8, and 12-weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patient with type 2 diabetes diagnosed according to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) guidelines serum glycated hemoglobin (HbA1c) level between 7 and 10% (53-86 mmol/mol) signed written informed consent form Exclusion Criteria: other types of diabetes mellitus patients with poor glycaemic control or unstable diabetes patients with known serious comorbidity and/ or with advanced macrovascular complications active bacterial infection or treatment with antibiotics within 3 weeks open wounds or skin lesions history of skin-related conditions or sensitivity to prolonged water immersion or exposure to pool chemicals severe psychiatric pathology or psychosis pregnancy or breastfeeding judgment by medical provider that heat therapy/ hydrotherapy poses an undue burden or risk participating in other ongoing clinical trials heat or balneotherapy in the past 3 months morbid obesity (body mass index > 40 kg/m2) steroid treatment active autoimmune diseases coronavirus disease 2019 (COVID-19) in the past 3 months
Facility Information:
Facility Name
Institute for Translational Medicine, University of Pécs
City
Pécs
ZIP/Postal Code
7624
Country
Hungary

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34808071
Citation
Sebok J, Edel Z, Vancsa S, Farkas N, Kiss S, Eross B, Torok Z, Balogh G, Balogi Z, Nagy R, Hooper PL, Geiger PC, Wittmann I, Vigh L, Dembrovszky F, Hegyi P. Heat therapy shows benefit in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Hyperthermia. 2021;38(1):1650-1659. doi: 10.1080/02656736.2021.2003445.
Results Reference
background
PubMed Identifier
22815343
Citation
Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1771-6. doi: 10.1161/ATVBAHA.111.241869.
Results Reference
background
PubMed Identifier
30389673
Citation
Salas-Salvado J, Diaz-Lopez A, Ruiz-Canela M, Basora J, Fito M, Corella D, Serra-Majem L, Warnberg J, Romaguera D, Estruch R, Vidal J, Martinez JA, Aros F, Vazquez C, Ros E, Vioque J, Lopez-Miranda J, Bueno-Cavanillas A, Tur JA, Tinahones FJ, Martin V, Lapetra J, Pinto X, Daimiel L, Delgado-Rodriguez M, Matia P, Gomez-Gracia E, Diez-Espino J, Babio N, Castaner O, Sorli JV, Fiol M, Zulet MA, Bullo M, Goday A, Martinez-Gonzalez MA; PREDIMED-Plus investigators. Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial. Diabetes Care. 2019 May;42(5):777-788. doi: 10.2337/dc18-0836. Epub 2018 Nov 2.
Results Reference
background
PubMed Identifier
27270841
Citation
Brunt VE, Howard MJ, Francisco MA, Ely BR, Minson CT. Passive heat therapy improves endothelial function, arterial stiffness and blood pressure in sedentary humans. J Physiol. 2016 Sep 15;594(18):5329-42. doi: 10.1113/JP272453. Epub 2016 Jun 30.
Results Reference
background
PubMed Identifier
30335579
Citation
Hoekstra SP, Bishop NC, Faulkner SH, Bailey SJ, Leicht CA. Acute and chronic effects of hot water immersion on inflammation and metabolism in sedentary, overweight adults. J Appl Physiol (1985). 2018 Dec 1;125(6):2008-2018. doi: 10.1152/japplphysiol.00407.2018. Epub 2018 Oct 18.
Results Reference
background
PubMed Identifier
24523032
Citation
Hooper PL, Balogh G, Rivas E, Kavanagh K, Vigh L. The importance of the cellular stress response in the pathogenesis and treatment of type 2 diabetes. Cell Stress Chaperones. 2014 Jul;19(4):447-64. doi: 10.1007/s12192-014-0493-8. Epub 2014 Feb 13.
Results Reference
background
PubMed Identifier
10498473
Citation
Hooper PL. Hot-tub therapy for type 2 diabetes mellitus. N Engl J Med. 1999 Sep 16;341(12):924-5. doi: 10.1056/NEJM199909163411216. No abstract available.
Results Reference
background
PubMed Identifier
35820741
Citation
Sebok J, Edel Z, Dembrovszky F, Farkas N, Torok Z, Balogh G, Peter M, Papp I, Balogi Z, Nusser N, Peter I, Hooper P, Geiger P, Eross B, Wittmann I, Vancsa S, Vigh L, Hegyi P. Effect of HEAT therapy in patiEnts with type 2 Diabetes mellitus (HEATED): protocol for a randomised controlled trial. BMJ Open. 2022 Jul 12;12(7):e062122. doi: 10.1136/bmjopen-2022-062122.
Results Reference
derived
Links:
URL
https://tm-centre.org/en/research/clinical-trials/
Description
Related info

Learn more about this trial

Heat Therapy in Patients With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs